1 2 Background: Current available treatments for Helicobacter pylori eradication are chosen 3 according to local clarithromycin and metronidazole resistance prevalence. The aim of this 4 study was to estimate, by means of molecular methods, both clarithromycin and metronidazole 5 resistance in gastric mucosa from patients infected with H.pylori. 6 7 Methods: A total of 191 DNA samples were analyzed. DNA was purified from gastric mucosa 8 obtained from patients who underwent an upper gastrointestinal endoscopy at an university 9 hospital from Santiago, Chile, between 2011 and 2014. H.pylori was detected by real-time 10 PCR. A 5'exonuclease assay was developed to detect A2142G and A2143G mutations among 11 H.pylori-positive samples. rdxA gene was sequenced in samples harboring A2142G and 12 A2143G mutations in order to detect mutations that potentially confer dual clarithromycin and 13 metronidazole resistance. 14 15 Results: Ninety-three (93) out of 191 DNA samples obtained from gastric mucosa were 16 H.pylori-positive (48.7%). Clarithromycin-resistance was detected in 29 samples (31.2% 17 [95%CI 22.0%-41.6%]). The sequencing of rdxA gene revealed that two samples harbored 18 truncating mutations in rdxA, one sample had an in-frame deletion, and 11 had amino acid 19 changes that likely cause metronidazole resistance. 20 21 Conclusions: We estimated a prevalence of clarithomycin-resistance of 31.8% in Santiago, 22
Background 1
Helicobacter pylori is a gram-negative bacillus that colonizes the gastric mucosa. The 2 infection is associated with both gastric and extragastric diseases such as peptic ulcer disease, 3 gastric atrophy, gastric adenocarcinoma, gastric MALT (mucosa-associated lymphoid tissue) 4 lymphoma, and iron deficiency anemia. The evidence strongly suggests that H.pylori 5 eradication is beneficial in treatment or prevention of those diseases [1] . One treatment for 6 H.pylori eradication is the triple-therapy that comprises clarithromycin, amoxicillin, and 7 proton pump inhibitor (PPI), nevertheless, triple-therapy is not recommended in regions with 8 high clarithomycin resistance rate [1] . Global claritrhomycin-resistance rates in adults are 9 contrasted among various countries, from 1% in The Netherlands to 37.6% in Italy [2] . In light 10 of this observation, the last Maastricht V/Florence consensus on management of H.pylori [1] 11 recommends that in high-clarithromycin resistance regions (>15% resistance prevalence), 12 quadruple therapy is necessary. If dual clarithromycin and metronidazole resistance is >15%, 13 bismuth-containing quadruple therapy is the recommended first-line treatment. 14 Clarithromycin belongs to the class of macrolide antibiotics. The mechanism of action 15 is the inhibition of protein synthesis of bacteria by binding to the 23S ribosomal subunit (23S 16 rRNA). Mutations in the peptidyltransferase region encoded in domain V of 23S rRNA are 17 responsible for macrolide resistance [3] . Three mutations in the 23S rRNA gene account for 18 nearly all clarithromycin-resistant (ClaR) strains: A2143G, A2142G and A2142C to a small 19 extent [3]. Standard method (antibiogram), after culture or molecular tests, can be used to 20 detect H.pylori and clarithromycin resistance directly from the gastric biopsy [1] . 21
Epidemiological studies evaluating regional clarithromycin resistance have been conducted 22 based on detection of A2142G and A2143G in DNA isolated from gastric biopsies [4, 5] . 23 Commercial tests detecting both mutations are available [3], performing at a sensitivity rate of 1 >94% and a specificity rate of >98.5% compared to the culture susceptibility test. Recently, 2
Tamayo et al. [6] found a high concordance between Etest for clarithromycin and 23S rRNA 3 mutations. To date, only Garrido and Toledo [7] have evaluated primary resistance of H.pylori 4 to clarithromycin in clinical isolates from Santiago, Chile. They found primary resistance in 10 5 out of 50 isolates by agar dilution. Resistant isolates harbor A2142G or A2143G mutations. 6
Metronidazole is a nitroimidazole synthesized as an inactive antibiotic prodrug. The 7 bactericidal effect of the drug is mainly explained by the cytotoxic effect of molecules 8 resulting from a reduction of metronidazole intracellularly in facultative anaerobic bacteria. 9
Reduction of metronidazole in H.pylori is mediated mainly by a nonessential oxygen-10 insensitive NADPH nitroreductase encoded by the rdxA gene. NADPH-flavin-oxidoreductase 11 (FrxA) is also involved in the reduction of metronidazole [3] . Various authors found that 12 metronidazole resistance arises from inactivating mutations in rdxA found only in resistant 13 isolates, and missense mutations have also been involved in metronidazole resistance [8] . On 14 the other hand, the role of inactivating mutations in the frxA gene is controversial since 15 truncating mutations have been found in sensitive isolates, and some studies report that frxA 16 mutations alone may not be enough to confer resistance [8] . Vallejos et al. [9] studied 17 resistance to clarithromycin and metronidazole in 50 isolates obtained from patients in 18 Santiago, Chile. Forty-five and twenty percent respectively were resistant, resulting in 13.2% 19 of the prevalence of dual clarithromycin and metronidazole resistance. 20
21
The aim of the present study was to estimate clarithomycin resistance in 93 clinical 22
isolates from Santiago, Chile. To do so, we developed a test to detect A2142G and A2143G 23 mutations in 23S gene by 5'nuclease assay. We also aimed to detect mutations in the rdxA gene 1 among ClaR isolates. sequencing. Both Sanger sequencing and 5'exonuclease allowed us to detect heteroresistance, 9
i.e., the coexistence of resistant and susceptible bacterial strains in the same patient [12]. 10
Sixteen (16) out of 93 H.pylori subjects were homoresistant to clarithromycin (17.2%). In 11 addition, we detected heteroresistance in 13 out of 93 patients (14.0%). 12
The rdxA gene was sequenced in 28 ClaR samples. One ClaR sample was not available 13 at the time of analysis. A nonsense substitution (H53stop) was found in one sample; and an 14 insertion of A at nucleotide 186, leading to a frameshift resulting in N73stop, was found in a 15 different sample. Therefore, two samples harbored truncating mutations in rdxA. One sample 16 had an in-frame deletion of 39 nucleotides which causes the deletion of amino acids 80 to 92 17 (ASALMVVCSLKPS). Table 1 shows the amino acid variations in rdxA found in ClaR 18 samples. 19 20
Discussion 21
A total of 29 out of the 93 H.pylori positive samples resulted resistant to clarithomycin 22 (31.2%). This estimation is higher than the 20% of ClaR reported by Garrido and Toledo in 23 Chile [7] . Taken together, ClaR resistance reported for Chile is above the suggested 15% 1 threshold to abandon triple-therapy, according to the recommendation of Maastricht 2 V/Florence consensus [1] . 3 Among 28 ClaR samples, two of them harbored truncating mutations and one an in-4 frame deletion in rdxA, and therefore are likely resistant to metronidazole. A total of 22 amino 5 acid substitutions was found. Thirteen of them (Q6H, T31E, H53R, L62V, R90K, H97T, 6 H97Y, G98S, A118T, V123T, V172I, E175Q, A183V) have been previously observed in 7 metronidazole-resistant (MtzR) as well as in metronidazole-sensitive strains [13-17]. 8
Therefore, those substitutions probably do not confer resistance to metronidazole. Four 9 substitutions (R16H, A67V, S88P and G162R) were found in 8 samples, and likely cause 10 resistance. R16H and S88P have been observed only in MtzR strains [13] [14] [15] . In fact, Arg 16 11 is one of the residues of RdxA that interacts with the cofactor flavin mononucleotide (FMN) 12
[18]. A67V corresponds to the replacement of a small alanine by a bulky valine in the protein 13 core, and is associated with resistance [8, 19] . Analysis from the crystallographic data of RdxA 14 reveals that G162 is involved in FMN binding [18] . 
